New Chairman of the Management Board - Adriaan Moelker takes over from Dr Jürgen Eck
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Personnel
BRAIN AG: New Chairman of the Management Board - Adriaan Moelker takes over from
Zwingenberg, Germany, 2 December 2019
Change at the top of the Management Board of BRAIN AG: The company announces, that the Supervisory Board appointed Adriaan Moelker to the Management Board with effect from 1 February 2020 and appointed him as the future Chairman of the Board (CEO). Dr Jürgen Eck, co-founder of BRAIN, Chief Technology Officer (CTO) for around 26 years as well as CEO since 1 August 2015, will resign from the Management Board at the end of this year and will leave the company by mutual agreement. Dr Eck will remain available to BRAIN as a consultant, in particular for the innovation pipeline.
Adriaan Moelker is currently Divisional President for Image Transfer Solutions and a member of the Flint Group Executive Management Team. He has held this position for six years, during which time he has made significant progress in terms of innovation and revenue. Previously, he was CEO of AB Enzymes GmbH in Darmstadt for nine years, during which time he also directed the company towards expansion. Because of this, as well as previous executive positions at Genencor (now DuPont) and marketing positions at DSM, Moelker has more than 20 years of professional experience in industrial biotechnology, where he developed a passion for customer-focused innovation. Moelker is native Dutch with a degree from Nyenrode Business University. He has been working and living with his family in the Frankfurt area for 14 years.
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.
|Company:||B.R.A.I.N. Biotechnology Research And Information Network AG|
|Darmstädter Straße 34-36|
|Phone:||+49 (0) 62 51 / 9331-0|
|Fax:||+49 (0) 62 51 / 9331-11|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||925369|
|End of News||DGAP News Service|